FINA Committee Meeting
Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at email@example.com.
MINUTES OF PROCEEDINGS
Meeting No. 56
Wednesday, May 10, 2000
The Standing Committee on Finance met at 3:36 p.m. this day, in Room 371, West Block, the Chair, Maurizio Bevilacqua, presiding.
Members of the Committee present: Maurizio Bevilacqua, Scott Brison, Roy Cullen, Nick Discepola, Ken Epp, Roger Gallaway, Albina Guarnieri, Lorne Nystrom, Karen Redman and Paul Szabo.
In attendance: From the Library of Parliament: Blayne Haggart, Researcher; Marion Wrobel, Senior Analyst.
Witnesses: From the Health Canada: Dann Michols, Director General, Therapeutic Products Programme, Health Protection Branch. From the Canada's Research-Based Pharmaceutical Companies: John Stewart, Executive Vice-President and General Manager, Purdue Pharma; Marc Desmarais, Vice-President, Federal Government Affairs, Rx&D; Arvind Mani, Director, Regulatory Affairs, Rx&D. From the Canadian Drug Manufacturers Association: Jim Keon, President; John Hems, Director, Regulatory Affairs, Apotex; Kent Major, Director, Regulatory Affairs and Clinical Research, Technilab.
Pursuant to Standing Order 108(2), the Committee resumed its study on Cost Recovery (See Minutes of Proceedings, Tuesday, May 9, 2000, Meeting No. 54).
Dann Michols, John Stewart and Jim Keon made statements and with the other witnesses in the round table, answered questions.
At 5:29 p.m., the Committee adjourned to the call of the Chair.
Clerk of the Committee